NICE - Endorsed Technology Appraisals 2011/2012
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisal Endorsement Process
The following technology appraisals were endorsed during 2011-12 using the process that came into effect on 28 September 2011. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2012
- TA 248 Exenatide (prolonged-release) for the treatment of type II diabetes
This guidance has been updated and replaced by NICE NG28 - Type 2 diabetes in adults: management, which was endorsed by the DoH in February 2016 - HSC (SQSD) (NICE NG28) 18/2016
- TA 247 Tocilizumab for the treatment of rheumatoid arthritis
This guidance has been replaced or partially updated by TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed, endorsed by the DoH in February 2016’ under each of the above.
- TA 246 Pharmalgen for the treatment of systemic reactions to bee and wasp venom allergy
- TA 70 Imatinib for the treatment of chronic myeloid leukaemia
This guidance has been partially updated by TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia & TA 426 -Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia, which were endorsed by the DoH in January 2017.
February 2012
- TA245 - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
- TA244 - Roflumilast for the management of severe chronic obstructive pulmonary disease
This guidance has been updated and replaced by TA461 - Roflumilast for treating chronic obstructive pulmonary disease, which was endorsed by the DoH in August 2017.
- TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma (Review of NICE TA110)
- TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (review)
- TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
- TA61 - Capecitabine and tegafur uracil for metastatic colorectal cancer
- TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
January 2012
- TA239 - Fulvestrant for the treatment of locally advanced or metastatic breast cancer
- TA238 - Tocilizumab for the Treatment of Systematic Idiopathic Juvenile Arthritis
- TA237 - Ranibizumab for the treatment of diabetic macular oedema
The above guidance has been replaced by TA 274 - Ranibizumab for treating diabetic macular oedema which was endorsed by DoH in March 2013
December 2011
- TA 233 - Golimumab for the treatment of ankylosing spondylitis
- This guidance has been replaced by NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis, which was endorsed by the DoH in February 2016.
- TA225 - Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
- This guidance has been replaced or partially updated by TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed, endorsed by the DoH in February 2016’ under each of the above.
- TA220 - Golimumab for the treatment of psoriatic arthritis
- TA219 - Everolimus for the second-line treatment of metastatic renal cell carcinoma
- This guidance has been updated and replaced by TA432 - Everolimus for advanced renal cell carcinoma after previous treatment, which was endorsed by the DoH in March 2017.
- TA218 - Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
- TA 203 - Liraglutide for the Treatment of Type II Disbetes Mellitus
- This guidance has been updated and replaced by NICE NG28 - Type 2 diabetes in adults: management, which was endorsed by the DoH in February 2016 - HSC (SQSD) (NICE NG28) 18/2016
- TA199 - Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis
- Note this guidance should be read in conjunction with NICE Technology Appraisal TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs which was endorsed by DoH in June 2017.
- TA197 - Dronedarone for the Treatment of Non-Permanent Atrial Fibrillation
- TA 186 - Certolizumab Pegol for the treatment of Rheumatois Arthritis
This guidance has been replaced or partially updated by TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed, endorsed by the DoH in February 2016’ under each of the above.
November 2011
- TA236 - Ticagrelor for the treatment of acute coronary syndromes
- TA235 - Mifamurtide for the treatment of osteosarcoma
- TA234 - Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs .
The above guidance has been replaced by TA 280 - Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs which was endorsed by DoH in May 2013
- TA232 - Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- TA230 - Bivalirudin for the treatment of ST-segment elevation myocardial infarction (STEMI) - ‘Note this guidance has been updated and replaced by NICE Clinical Guideline NG185 - Acute coronary syndromes, which was endorsed by the DoH in September 2021'
- TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO)
- TA228 - Bortezomib and Thalidomide for the first-line treatment of multiple myeloma
- TA227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
- TA226 - Ritixumab for the maintenance treatment of follicular non-Hodgkin's lymphoma following response to first-line chemotherapy
- TA223 - Cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
- TA222 - Trabectedin for the treatment of relapsed ovarian cancer
- This guidance has been updated and replaced by TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer, which was endorsed by the DoH in May 2016.
- TA221 - Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura
- TA216 - Bendamustine for the treatment of chronic lymphocytic leukaemia
- TA215 - Pazopanib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (related to TA169)
The above guidance has been re-issued after a change to the patient access scheme. Recommendation 1.1 of the guidance has been updated (August 2013).
- TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
- TA198 - Tocizilumab for rheumatoid arthritis
Please note that the above appraisal has been updated and replaced by TA 247
- TA195 - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for Treatment of Rheumatoid Arthritis after failure of a TNF inhibitor
- TA193 - Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukaemia
- TA190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer
- TA188 - Human growth hormone (somatropin) for the treatment of growth failure in children (review)
- TA185 - Trabectedin for the Treatment of Advanced Soft Tissue Sarcoma
- TA169 - Sunitinib for the Treatment of Renal Cell Carcinoma (related to TA215
- TA166 - Hearing Impairment - cochlear implants for severe to profound deafness in children and adults
- This guidance has been updated and replaced by TA566 - Cochlear implants for children and adults with severe to profound deafness, which was endorsed by the DoH in May 2019.
Endorsed With Caveats
November 2011
- TA75 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (related to TA200)
- This guidance has been partially updated by ‘Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C’ NICE Technology Appraisal guidance TA200. The elements of TA75 which have been updated and replaced are:
- section 1.2, bullet 3 only
- section 1.4 of TA75 for adults who are eligible for shortened courses of combination therapy (as described in section 1.2 of TA200)
- section 1.7, bullet 1 only
- All other recommendations in TA75 still stand
- TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease (Includes a review of NICE Technology Appraisal TA40)
It should be noted that continued therapy should be carefully reconsidered in a patient not responding to infliximab and adalimumab in the treatment of Crohn’s disease in accordance with the time period set out in the respective manufacturers’ Summary of Product Characteristics.
- TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (related to TA75)
In June 2011, sections 3.11, 3.12 and 4.1.5 of the guidance were amended to correct an error in the stated dose of ribavirin. The doses of ribavirin should be in mg (milligrams), and not micrograms. Any copies of the guidance printed before this date should be destroyed
Not Endorsed as Applicable to Northern Ireland
None
Endorsed Under Previous Process
The following NICE Technology Appraisals were endorsed by DoH during 2011-12 under the process which was in place prior to 28 September 2011.
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA86 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Note: This guidance has been partially updated by TA209)
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA191 - Capecitabine for the treatment of Advanced Gastric Cancer
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA201 - Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children aged 6-12 Years
- This guidance has been replaced by TA 278 - Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults which was endorsed by DoH in May 2013.
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA202 - Ofatumumab for the Treatment of Chronic Lymphocytic Leukaemia Refractory to Fludarabine and Alemtuzumab
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA204 - Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA205 - Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
- This guidance has been replaced by TA 293 - Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (review of technology appraisal 205) which was endorsed by DoH in August 2013.
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA209 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Part update of NICE TA86)
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA212 - Colorectal Cancer (metastatic) - Bevacizumab in combination with Oxaliplatin & either 5-fluorouracil plus Folinic Acid or Capecitabine
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA213 - Aripiprazole for Schizophrenia in People Aged 15-17 Years
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA214 - Bevacizumab in Combination with a Taxane for the First-line Treatment of Metastatic Breast Cancer
National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA217 - Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease
- HSC (SQSD) (NICE) 32/2011
- This guidance has been partially updated by NICE Clinical Guideline NG97 - Dementia: assessment, management and support for people living with dementia and their carers, which was endorsed by the DoH in August 2018.